SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (16897)12/13/1998 12:38:00 AM
From: VLAD  Respond to of 23519
 
The media will probably again be hyping the generic drug apomorphine as a great ED drug as I have seen before. For those who are at all curious about the so called "competition" here is an interesting abstract on apomorphine:

ncbi.nlm.nih.gov

Remember now, only works in psychogenic ED and has a high incidence of nausea and vomiting when used. No competition. Same can be said for Vasomax and those so called ED creams. You already know why.



To: Frostman who wrote (16897)12/13/1998 11:56:00 AM
From: John M. Gelnieau  Respond to of 23519
 
Hey Frosty,

Good analysts always deal in hindsight. IMHO of course.

A few examples:

Upgraded CPQ after it went from 23 to 35. 40 target.
Upgraded COMS after it went from 25 to 35. 40 target.
Upgraded Upgraded SUNW after it went from 46 to 64.

And the biggest analyst upgrade of the fall, after the dow went from 7500 to about 8400 they proclaimed dow 9000 by Christmas.

Let's keep those analysts away a little longer and let this thing get rockin' and rollin'.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News